HS-20094 clinical trials
Also written HS-20094.
How each study uses HS-20094 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HS-20094 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test HS-20094, phase 3 first.
- Mar 2027A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise AlonePhase 3 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Mar 2027A Phase 3 Study of HS-20094 in Patients With T2DMPhase 3 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses HS-20094 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise AloneNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07156500Written as HS-20094 Injection
- A Phase 3 Study of HS-20094 in Patients With T2DMNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07156539Written as HS-20094 Injection
- A Study of HS-20094 in Overweight or Obese ParticipantsRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07057674Written as HS-20094 AI pen;
- A Study of HS-20094 in Chinese Adults With Overweight or ObesityCompletedPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06839664Written as HS-20094 injection
- A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsCompletedPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06118021Written as HS-20094
- A Study of HS-20094 in T2DM ParticipantsCompletedPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06118008Written as HS-20094 5mg
- A Study of HS-20094 in Patients With T2DMCompletedPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06901648Written as HS-20094
- A Study of HS-20094 in Healthy ParticipantsStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05116410Written as HS-20094